ProPharma Deploys Proprietary AI Capability to Accelerate ANDA Submission Development for Regulatory CRO Clients

• ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, has announced the deployment of a proprietary AI-assisted capability designed to enhance how its regulatory teams develop Abbreviated New Drug Application (ANDA) submissions — reducing manual authoring effort while maintaining scientific rigor and regulatory quality.

• The capability, which intelligently aggregates and analyzes information from multiple data sources and document formats to generate structured first drafts, is the latest milestone in ProPharma’s enterprise-wide Technology Enablement Strategy, which is embedding purpose-built AI and automation tools across regulatory affairs, CRO services, pharmacovigilance, quality and compliance, and medical information service lines.

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, announced on July 8, 2026, from Raleigh, North Carolina, the deployment of a proprietary AI-assisted capability to enhance ANDA submission development for its regulatory CRO clients. The tool was purpose-built to support ProPharma’s internal regulatory teams in the preparation of Abbreviated New Drug Application submissions — generating structured first drafts by intelligently aggregating and analyzing information across multiple data sources and document formats, and enabling regulatory experts to redirect time toward scientific evaluation, strategic guidance, quality review, and client collaboration.

The AI-assisted capability is designed to improve four core dimensions of ANDA submission quality and efficiency: consistency and completeness of submission content, traceability throughout the development process, management of regulatory questions and deficiency responses, and overall authoring timeline reduction. For generic drug sponsors outsourcing ANDA preparation to ProPharma, the practical outputs include accelerated submission timelines, reduced manual document authoring effort, and better utilization of regulatory resource capacity — all while maintaining the quality and compliance standards expected by global health authorities including the FDA. The capability operates within ProPharma’s existing expert-led delivery model: human oversight and regulatory judgment remain central to every engagement, with AI functioning as an efficiency and consistency enhancer rather than a replacement for scientific expertise.

The ANDA capability represents the latest deployment under ProPharma’s Technology Enablement Strategy, an enterprise-wide initiative to integrate proprietary technology, intelligent automation, and artificial intelligence into expert-led service delivery across the organization. The strategy spans regulatory affairs, CRO services, pharmacovigilance, quality and compliance, medical information, and consulting, with each deployment designed to improve efficiency, consistency, scalability, and client outcomes without displacing the scientific expertise and regulatory judgment that underpin ProPharma’s service model. ProPharma serves biotech, pharmaceutical, and medical device organizations globally, with more than 25 years of experience supporting regulatory submissions, clinical research, compliance, and life sciences consulting.

The deployment signals a broader shift occurring across the regulatory CRO sector, where AI-assisted document generation is moving from experimental to operational. By building proprietary, purpose-specific AI tools rather than deploying off-the-shelf solutions, ProPharma is positioning its regulatory service delivery model around IP-protected capabilities — differentiating its ANDA submission service from standard outsourcing relationships and creating a structural efficiency advantage that benefits both the company and its clients as submission volumes and complexity continue to grow.

“The future of regulatory submissions is not about replacing experts with technology. It’s about empowering experts with better tools. By combining human expertise with AI-enabled efficiencies, we are helping clients reduce authoring timelines, improve operational effectiveness, and maintain the scientific rigor and regulatory excellence that have always been central to ProPharma’s approach in a more cost-effective way.”

Matthew Weinberg, President, Regulatory Sciences, ProPharma